Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning. Hudson also said that the French pharma is not expecting a significant impact from the US legislation targeting Chinese service providers given the